Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2020-08-07 Capital/Financing Update
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for public offering. It includes detailed information about the securities to be offered, such as common stock, preferred stock, debt securities, and warrants, with a maximum aggregate offering price. The document is a registration statement and prospectus, not a financial report, earnings release, or management discussion. It is related to capital raising activities and financing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the actual registration statement, not just an announcement or notice.
2020-08-07 English
10-Q
Interim / Quarterly Report Q2 2020
2020-08-04 English
FORM 4
Director's Dealing
2020-08-04 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated July 30, 2020, reporting the company's financial results and business highlights for the quarter ended June 30, 2020. It specifically mentions that a press release announcing these results is furnished as an exhibit. The document itself is short (3503 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, such a document is classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results with key highlights, not a full interim or annual report.
2020-07-30 English
FORM 4
Director's Dealing
2020-07-06 English
FORM 4
Director's Dealing
2020-07-01 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.